Day One Biopharmaceuticals, Inc. (“Day One”) is a clinical-stage biopharmaceutical company focused on pediatric cancer. Day One’s lead product candidate, tovorafenib (DAY101) is an oral, brain-penetrant, highly-selective type II rapidly accelerated fibrosarcoma, or RAF, kinase inhibitor. Day One has initiated and fully enrolled a pivotal Phase 2 trial of tovorafenib as a monotherapy for pediatric patients with relapsed or progressive low-grade glioma harboring an activating BRAF alteration. Pediatric low-grade glioma is the most common brain tumor diagnosed in children.